Provider of drugs designed to harness the body's natural process to control protein levels. The company's drugs control protein levels and provide an opportunity for a new therapeutic approach to alter the development and progression of a broad range of diseases, enabling healthcare providers to treat proliferative and degenerative diseases.
The company raised $17.03 million of Series C venture funding from Celgene (NASDAQ: CELG) and other undisclosed investors on September 16, 2015, putting the company's pre-money valuation at $210 million.
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.